NCT04756726View on ClinicalTrials.gov

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

April 27, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Multiple MyelomaLymphoma, Non-Hodgkin's
Interventions
DRUG

cemsidomide

oral cemsidomide

DRUG

Dexamethasone Oral

oral dexamethasone \[ ≤75 years old: 40 mg once per week (QW) on days 1, 8, 15, and 22; \>75 Years old: 20 mg QW on days 1, 8, 15, and 22\]

Trial Locations (13)

10029

Mt Sinai Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

30322

Emory University Hospital, Atlanta

32224

Mayo Clinic, Jacksonville

37203

Tennessee Oncology (Sarah Cannon Research Institute), Nashville

53226

Medical College of Wisconsin, Milwaukee

55905

Mayo Clinic, Rochester

63110

Washington University School of St. Louis, St Louis

80218

Colorado Blood Cancer Institute (Sarah Cannon Research Institute), Denver

85054

Mayo Clinic, Phoenix

94143

University of California-San Francisco, San Francisco

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

C4 Therapeutics, Inc.

INDUSTRY